(MENAFN- GetNews)

The Key Carcinoid Syndrome Companies in the market include - Ipsen Biopharmaceuticals, Lexicon Pharmaceuticals, Crinetics Pharmaceuticals, Sanwa Kagaku Kenkyusho, Novartis, Ipsen, and others.

DelveInsight's “Carcinoid Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Carcinoid Syndrome, historical and forecasted epidemiology as well as the Carcinoid Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Carcinoid Syndrome, offering comprehensive insights into the Carcinoid Syndrome revenue trends, prevalence, and treatment landscape. The report delves into key Carcinoid Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Carcinoid Syndrome therapies. Additionally, we cover the landscape of Carcinoid Syndrome clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Carcinoid Syndrome treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Carcinoid Syndrome space.

To Know in detail about the Carcinoid Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Carcinoid Syndrome Market Forecast

Some of the key facts of the Carcinoid Syndrome Market Report:

• The Carcinoid Syndrome market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In November 2025, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial-a multicenter, randomized, double-blind, placebo-controlled study designed to assess the safety and effectiveness of once-daily oral paltusotine in adults with carcinoid syndrome resulting from well-differentiated neuroendocrine tumors. The Phase 3 trial follows encouraging Phase 2 results, where paltusotine showed rapid and durable improvements in carcinoid syndrome symptoms, including reductions in flushing episodes and bowel movement frequency.

• A carcinoid tumor is an uncommon form of neuroendocrine tumor, typically arising in the gastrointestinal system or the lungs, and it is observed in fewer than 3 out of every 100,000 people annually.

• Less than 10% of individuals with carcinoid tumors experience noticeable symptoms, though the likelihood of symptoms can differ depending on where the tumor is located.

• Around 40% of gastrointestinal carcinoid tumors originate in the small intestine, whereas carcinoid tumors of the lung account for only about 1–2% of all lung cancer cases.

• Key Carcinoid Syndrome Companies: Ipsen Biopharmaceuticals, Lexicon Pharmaceuticals, Crinetics Pharmaceuticals, Sanwa Kagaku Kenkyusho, Novartis, Ipsen, and others

• Key Carcinoid Syndrome Therapies: SOMATULINE AUTOGEL /SOMATULINE DEPOT (lanreotide), SANDOSTATIN LAR DEPOT (octreotide acetate), XERMELO (telotristat ethyl), PALSONIFY (paltusotine), Octreotide, Lanreotide, Telotristat etiprate, Paltusotine, Pasireotide (SOM230), and others

• The Carcinoid Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Carcinoid Syndrome pipeline products will significantly revolutionize the Carcinoid Syndrome market dynamics.

Carcinoid Syndrome Overview

Carcinoid Syndrome is a group of symptoms caused by hormone-secreting neuroendocrine tumors, typically originating in the gastrointestinal tract or lungs. It occurs when these tumors release excessive serotonin and other chemicals into the bloodstream, leading to symptoms such as flushing, diarrhea, wheezing, and heart valve complications. The syndrome is more common in cases where the tumor has metastasized to the liver. Treatment includes somatostatin analogs (e.g., octreotide, lanreotide), targeted therapies, and supportive care to manage symptoms and improve quality of life.

Get a Free sample for the Carcinoid Syndrome Market Forecast, Size & Share Analysis Report:

Carcinoid Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Carcinoid Syndrome Epidemiology Segmentation:

The Carcinoid Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Carcinoid Syndrome

• Prevalent Cases of Carcinoid Syndrome by severity

• Gender-specific Prevalence of Carcinoid Syndrome

• Diagnosed Cases of Episodic and Chronic Carcinoid Syndrome

Download the report to understand which factors are driving Carcinoid Syndrome epidemiology trends @ Carcinoid Syndrome Epidemiology Forecast

Carcinoid Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Carcinoid Syndrome market or expected to get launched during the study period. The analysis covers Carcinoid Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Carcinoid Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Carcinoid Syndrome Therapies and Key Companies

• SOMATULINE AUTOGEL /SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals

• SANDOSTATIN LAR DEPOT (octreotide acetate): Novartis

• XERMELO (telotristat ethyl): Lexicon Pharmaceuticals

• PALSONIFY (paltusotine): Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho

• Octreotide: Novartis

• Lanreotide: Ipsen

• Telotristat etiprate: Lexicon Pharmaceuticals

• Paltusotine: Crinetics Pharmaceuticals Inc

• Pasireotide (SOM230): Novartis

Discover more about therapies set to grab major Carcinoid Syndrome market share @ Carcinoid Syndrome Treatment Landscape

Carcinoid Syndrome Market Drivers

• Increasing Prevalence of Neuroendocrine Tumors (NETs)

• Advancements in Treatment Options

• Growing Awareness and Early Diagnosis

• Expanding Research and Development

• Supportive Regulatory Policies

• Rising Healthcare Expenditure

Carcinoid Syndrome Market Barriers

• High Cost of Treatment

• Limited Awareness in Underdeveloped Regions

• Side Effects of Available Therapies

• Lack of Curative Treatment

• Slow Drug Development Process

• Market Competition and Patent Expirations

Scope of the Carcinoid Syndrome Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Carcinoid Syndrome Companies: Ipsen Biopharmaceuticals, Novartis, Lexicon Pharmaceuticals, Crinetics Pharmaceuticals, Sanwa Kagaku Kenkyusho, Ipsen, and others

• Key Carcinoid Syndrome Therapies: SOMATULINE AUTOGEL /SOMATULINE DEPOT (lanreotide), SANDOSTATIN LAR DEPOT (octreotide acetate), XERMELO (telotristat ethyl), PALSONIFY (paltusotine), Octreotide, Lanreotide, Telotristat etiprate, Paltusotine, Pasireotide (SOM230), and others

• Carcinoid Syndrome Therapeutic Assessment: Carcinoid Syndrome current marketed and Carcinoid Syndrome emerging therapies

• Carcinoid Syndrome Market Dynamics: Carcinoid Syndrome market drivers and Carcinoid Syndrome market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

• Carcinoid Syndrome Unmet Needs, KOL's views, Analyst's views, Carcinoid Syndrome Market Access and Reimbursement

To know more about Carcinoid Syndrome companies working in the treatment market, visit @ Carcinoid Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. Carcinoid Syndrome Market Report Introduction

2. Executive Summary for Carcinoid Syndrome

3. SWOT analysis of Carcinoid Syndrome

4. Carcinoid Syndrome Patient Share (%) Overview at a Glance

5. Carcinoid Syndrome Market Overview at a Glance

6. Carcinoid Syndrome Disease Background and Overview

7. Carcinoid Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Carcinoid Syndrome

9. Carcinoid Syndrome Current Treatment and Medical Practices

10. Carcinoid Syndrome Unmet Needs

11. Carcinoid Syndrome Emerging Therapies

12. Carcinoid Syndrome Market Outlook

13. Country-Wise Carcinoid Syndrome Market Analysis (2020–2034)

14. Carcinoid Syndrome Market Access and Reimbursement of Therapies

15. Carcinoid Syndrome Market Drivers

16. Carcinoid Syndrome Market Barriers

17. Carcinoid Syndrome Appendix

18. Carcinoid Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

MENAFN03122025003238003268ID1110434117